

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 November 2022 (03.11.2022)



(10) International Publication Number
WO 2022/229922 A1

(51) International Patent Classification:

C07K 16/40 (2006.01) A61P 19/02 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/IB2022/054001

(22) International Filing Date:

29 April 2022 (29.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/182,561 30 April 2021 (30.04.2021) US
63/362,372 01 April 2022 (01.04.2022) US

(71) Applicants: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH). **MERCK PATENT GMBH** [DE/DE];
Frankfurter Str. 250, 64293 Darmstadt (DE).

(72) Inventors: **FLESCH, Gérard**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **GUEHRING, Hans**; Merck
Patent GmbH, Frankfurter Str. 250, 64293 Darmstadt (DE).
SCHIEKER, Matthias Klaus; Novartis Pharma AG, Post-
fach, 4002 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse
35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

WO 2022/229922 A1

(54) Title: METHODS FOR THE ADMINISTRATION OF ADAMTS BINDING IMMUNOGLOBULINS

(57) Abstract: Disclosed herein are methods and dosage regimens for the treatment of osteoarthritis (e.g., knee osteoarthritis). The methods and dosage regimens comprise administration of an ADAMTS5 inhibiting polypeptide in a therapeutically effective amount.